Increased levels and adipose tissue expression of visfatin in morbidly obese women: The relationship with pro-inflammatory cytokines

Clinical Endocrinology

Volumn 77, Issue 5, 2012, Pages 691-698

  Terra, Ximena ^a   Auguet, Teresa ^a   Quesada, Isabel ^a   Aguilar, Carmen ^a   Luna, Anna Maria ^a   Hernández, Mercé ^b   Sabench, Fátima ^b   Porras, José Antonio ^a   Martínez, Salomé ^a   Lucas, Anna ^c   Pellitero, Silvia ^c   Llutart, Jordi ^a   Del Castillo, Daniel ^b   Richart Jurado, Cristóbal ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 6; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BARIATRIC SURGERY; BLOOD SAMPLING; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MORBID OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPAIN; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADULT; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY, MORBID; REAL-TIME POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867263517     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04327.x     Document Type: Article

References (37)

1. Gustafson, B., (2010) Adipose tissue, inflammation and atherosclerosis. Journal of Atherosclerosis and Thrombosis, 17, 332-341.
2. Wang, Z., &, Nakayama, T., (2010) Inflammation, a link between obesity and cardiovascular disease. Mediators of Inflammation, 2010, 535918.
3. Blüher, M., (2009) Adipose tissue dysfunction in obesity. Experimental and Clinical Endocrinology and Diabetes, 117, 241-250.
4. Samal, B., Sun, Y., Stearns, G., et al. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Molecular and Cellular Biology, 14, 1431-1437.
5. Rongvaux, A., Shea, R.J., Mulks, M.H., et al. (2002) Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. European Journal of Immunology, 32, 3225-3234. (Pubitemid 35414880)
6. Fukuhara, A., Matsuda, M., Nishizawa, M., et al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 307, 426-430. (Pubitemid 40139988)
7. Revollo, J.R., Körner, A., Mills, K.F., et al. (2007) Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metabolism, 6, 363-375. (Pubitemid 350011996)
8. Brown, J.E.P., Onyango, D.J., Ramanjaneya, M., et al. (2010) Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic β-cells. Journal of Molecular Endocrinology, 44, 171-178.
9. Skop, V., Kontrová, K., Zídek, V., et al. (2010) Autocrine effects of visfatin on hepatocyte sensitivity to insulin action. Physiological Research, 59, 615-618.
10. Curat, C.A., Wegner, V., Sengenès, C., et al. (2006) Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia, 49, 744-747. (Pubitemid 43357549)
11. Chang, Y., Chang, T., Lee, W., et al. (2010) The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids. Metabolism: Clinical and Experimental, 59, 93-99.
12. Moschen, A.R., Kaser, A., Enrich, B., et al. (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. Journal of Immunology, 178, 1748-1758. (Pubitemid 46154646)
13. Jia, S.H., Li, Y., Parodo, J., et al. (2004) Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. Journal of Clinical Investigation, 113, 1318-1327. (Pubitemid 39069931)
14. Ye, S.Q., Simon, B.A., Maloney, J.P., et al. (2005) Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. American Journal of Respiratory and Critical Care Medicine, 171, 361-370. (Pubitemid 40223404)
15. Otero, M., Lago, R., Gomez, R., et al. (2006) Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 65, 1198-1201. (Pubitemid 44277396)
16. Stofkova, A., (2010) Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocrine Regulations, 44, 25-36.
17. Berndt, J., Klöting, N., Kralisch, S., et al. (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes, 54, 2911-2916. (Pubitemid 41401086)
18. Chen, M.P., Chung, F.M., Chang, D.M., et al. (2006) Elevated plasma level of visfatin/Pre-B cell colony-enhancing factor in patients with Type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism, 91, 295-299.
19. Dogru, T., Sonmez, A., Tasci, I., et al. (2007) Plasma visfatin levels in patients with newly diagnosed and untreated Type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Research and Clinical Practice, 76, 24-29. (Pubitemid 46240362)
20. López-Bermejo, A., Chico-Julià, B., Fernàndez- Balsells, M., et al. (2006) Serum visfatin increases with progressive β-cell deterioration. Diabetes, 55, 2871-2875. (Pubitemid 44923689)
21. Haider, D.G., Schindler, K., Schaller, G., et al. (2006) Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. Journal of Clinical Endocrinology and Metabolism, 91, 1578-1581.
22. Catalán, V., Gómez-Ambrosi, J., Rodríguez, A., et al. (2011) Association of increased visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Nutrition, Metabolism, and Cardiovascular Diseases, 21, 245-253.
23. Chang, Y.H., Chang, D.M., Lin, K.C., et al. (2011) Visfatin in overweight/obesity, Type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: a meta-analysis and systemic review. Diabetes/metabolism Research and Reviews, 27, 515-527.
24. Pagano, C., Pilon, C., Olivieri, M., et al. (2006) Reduced plasma visfatin/Pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. Journal of Clinical Endocrinology and Metabolism, 91, 3165-3170. (Pubitemid 44271773)
25. Moschen, A.R., Molnar, C., Wolf, A.M., et al. (2009) Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. Journal of Hepatology, 51, 765-777.
26. De Luis, D.A., Gonzalez Sagrado, M., Conde, R., et al. (2008) Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients. Nutrition, 24, 517-521.
27. Choi, K.M., Kim, J.H., Cho, G.J., et al. (2007) Effect of exercise training on plasma visfatin and eotaxin levels. European Journal of Endocrinology, 157, 437-442. (Pubitemid 350018446)
28. Körner, A., Garten, A., Blüher, M., et al. (2007) Molecular characteristics of serum visfatin and differential detection by immunoassays. Journal of Clinical Endocrinology and Metabolism, 92, 4783-4791. (Pubitemid 350223461)
29. WHO (2006) Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. WHO Document Production Services, Geneva, Switzerland, 1-46.
30. Wallace, T.M., Levy, J.C., &, Matthews, D.R., (2004) Use and abuse of HOMA modeling. Diabetes Care, 27, 1487-1495. (Pubitemid 38680001)
31. Terra, X., Auguet, T., Porras, J.A., et al. (2010) Anti-inflammatory profile of FTO gene expression in adipose tissues from morbidly obese women. Cellular Physiology and Biochemistry, 26, 1041-1050.
32. Araki, S., Dobashi, K., Kubo, K., et al. (2008) Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity, 16, 384-388. (Pubitemid 351271920)
33. Zahorska-Markiewicz, B., Olszanecka-Glinianowicz, M., Janowska, J., et al. (2007) Serum concentration of visfatin in obese women. Metabolism: Clinical and Experimental, 56, 1131-1134. (Pubitemid 47021180)
34. Varma, V., Yao-Borengasser, A., Rasouli, N., et al. (2006) Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. Journal of Clinical Endocrinology and Metabolism, 92, 666-672.
35. Hug, C., &, Lodish, H.F., (2005) Visfatin: a new adipokine. Science, 307, 366-367. (Pubitemid 40139968)
36. MacLaren, R., Cui, W., &, Cianflone, K., (2007) Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes, Obesity & Metabolism, 9, 490-497. (Pubitemid 47018512)
37. Bala, M., Martin, J., Kopp, A., et al. (2011) In vivo suppression of visfatin by oral glucose uptake: evidence for a novel incretin-like effect by Glucagon-Like Peptide-1 (GLP-1). Journal of Clinical Endocrinology and Metabolism, 96, 2493-2501.